Citrate pharmacokinetics and metabolism in cirrhotic and noncirrhotic critically ill patients. - Wikidata - wikimedia - TriplyDB

Citrate pharmacokinetics and metabolism in cirrhotic and noncirrhotic critically ill patients.

Citrate pharmacokinetics and metabolism in cirrhotic and noncirrhotic critically ill patients.

http://www.wikidata.org/entity/Q44609131

about

Parenteral calcium for intensive care unit patients Citrate anticoagulation: Are blood donors donating bone?Clinical review: Patency of the circuit in continuous renal replacement therapy Citrate anticoagulation during post-dilution hemodiafiltration with a high cut-off (Theralite) membrane.Anticoagulation techniques in apheresis: from heparin to citrate and beyond.Advances in continuous renal replacement therapy: citrate anticoagulation update.Regional citrate anticoagulation for RRTs in critically ill patients with AKI.Massive transfusion and massive transfusion protocol Continuous venovenous haemofiltration with citrate-buffered replacement solution is safe and efficacious in patients with a bleeding tendency: a prospective observational study.Citrate Pharmacokinetics in Critically Ill Patients with Acute Kidney Injury Molecular adsorbent recirculating system and hemostasis in patients at high risk of bleeding: an observational study.Clinical review: anticoagulation for continuous renal replacement therapy--heparin or citrate?Simplified Citrate Anticoagulation for CRRT Without Calcium Replacement Safety and efficacy of regional citrate anticoagulation in continuous venovenous hemodialysis in the presence of liver failure: the Liver Citrate Anticoagulation Threshold (L-CAT) observational study.Metabolic and nutritional aspects of acute renal failure in critically ill patients requiring continuous renal replacement therapy.A new prescription model for regional citrate anticoagulation in therapeutic plasma exchanges.Albumin regeneration in liver support-comparison of different methods.Total-to-ionized calcium ratio predicts mortality in continuous renal replacement therapy with citrate anticoagulation in critically ill patients.Continuous venovenous hemodialysis with regional citrate anticoagulation in patients with liver failure: a prospective observational study Bench-to-bedside review: Citrate for continuous renal replacement therapy, from science to practice.Citrate pharmacokinetics and calcium levels during high-flux dialysis with regional citrate anticoagulation.Plasma exchange induces vitamin D deficiency.Acid-base and electrolyte abnormalities during renal support for acute kidney injury: recognition and management.Therapeutic plasma exchange for the treatment of pediatric renal diseases in 2013.Effectiveness and Safety Assessment of Citrate Anticoagulation During Albumin Dialysis in Comparison to Other Methods of Anticoagulation.Extracorporeal detoxification for hepatic failure using molecular adsorbent recirculating system: depurative efficiency and clinical results in a long-term follow-up.A prospective randomized open-label crossover trial of regional citrate anticoagulation vs. anticoagulation free liver dialysis by the Molecular Adsorbents Recirculating System.Role of citrate and other methods of anticoagulation in patients with severe liver failure requiring continuous renal replacement therapy.Is Regional Citrate Anticoagulation the Future of Hemodialysis?Citrate modulates lipopolysaccharide-induced monocyte inflammatory responses.Model-Based Assessment of Plasma Citrate Flux Into the Liver: Implications for NaCT as a Therapeutic Target Regional citrate anticoagulation for slow continuous ultrafiltration: risk of severe metabolic alkalosis.Transition From Heparin to Citrate Anticoagulation for Continuous Renal Replacement Therapy: Safety, Efficiency, and Cost.Citrate anticoagulation for continuous renal replacement therapy (CRRT) in patients with acute kidney injury admitted to the intensive care unit.Citrate pharmacokinetics at high levels of circuit citratemia during coupled plasma filtration adsorption.Metabolic phenotyping for enhanced mechanistic stratification of chronic hepatitis C-induced liver fibrosis.Selective cytopheretic inhibitory device with regional citrate anticoagulation and portable sorbent dialysis.Citrate anticoagulation for continuous renal replacement therapy in critically ill patients: success and limits.Lactate clearance and metabolic aspects of continuous high-volume hemofiltration.Kidneys in chronic liver diseases.

P2860

Q24240944-A88AC16B-DB27-446C-BE7F-D4B062EC7876 Q30252024-9218BBA1-1365-46DC-B644-56B79E8AE39D Q33375906-8A0937B7-C24A-4A85-92D3-C52DB430B51E Q33395569-A759A389-0B5C-48C8-906E-22F0014829C3 Q33400909-09927489-42AE-4CB6-AD8A-379504A547AD Q33403996-ED3697F8-9D00-42B4-9CAD-96313FDD8123 Q34629661-20FEC950-3365-4312-91B0-970EAF85C732 Q34659793-4498CBD0-ADC4-4A71-B800-79DB5A5FA71F Q34676665-8B7A0CA3-949F-4586-8FD2-32768575DA4C Q34792965-59463FE3-619C-4720-8F7F-506693324DD2 Q34999188-4D069C0B-8AF0-44AD-B22C-4B92D8288C9A Q35567100-8D4130A4-7515-4CF1-BBEA-B9DBB023357B Q35806341-87F88A95-E07A-45B0-8A80-EBB97E6E7725 Q36104484-0D5652E2-4F73-4E11-8784-0A1F875BC519 Q36278335-9C34DEDC-C97A-4629-93A5-7011EA8E23B4 Q36294493-C7D7C8F2-D50C-47D1-9A84-6E6C7F111D5E Q36473219-14847359-B0B4-422C-B6E0-E948E925E448 Q36633658-9EA71D05-E621-4D26-BF4B-6FE57E916835 Q36634057-D40983D1-46A8-4AD9-8554-D0FDBCB9CD5C Q36902584-7992E1AF-B5EB-4E21-BC4F-D72630583CA4 Q37231751-AD8E29C4-BDF2-45B5-ADCE-39E09DDAD697 Q37527914-40DCC850-E738-485D-AA16-E9D570ACA988 Q38055290-86B6879B-E360-4C7F-ADA3-C7A4040B2D0F Q38118112-1FC66F57-20BA-47D4-A906-62843AEA8CAD Q38432418-6B05F6D6-DD0B-4423-B100-5796738B7C29 Q38453564-6BC2DFB4-0C26-4887-9830-832FCD328AF8 Q38460284-D1460CE6-35D0-442E-B496-02C9AA677B6C Q38463548-4EBFDB8A-3AEC-400D-9E0E-51AD90290242 Q38851933-46C84E42-B04C-4D52-9B74-D460153976D1 Q38916731-6CA664FA-35EB-42FA-8426-786E60217FD4 Q39566398-2795D9FD-A1B6-4B22-8A80-72A8D0A31FA6 Q39720522-8B6D909A-3E1B-4573-B8B4-6B605C5F0CE6 Q40112499-F4C79864-6077-4D07-B43F-EA0AB18A8316 Q40325454-DBE01825-5053-448E-AE3D-2EA4DFA81EBB Q40603847-E5546DE8-ADF0-4555-9959-38045BEC0D2B Q41658253-9017C18D-AD33-4EA1-9546-D62637DDE906 Q41973313-134321D8-98B4-49D1-BD84-EBFE7D9511F4 Q42001643-3826B508-11F5-4BBE-B0D5-DE58731C659A Q42392718-13D78461-349D-4E7F-95C3-AF47299E508F Q43209206-691CC3DF-80FF-4EEC-9A43-B0F636D70BA6

P2860

Citrate pharmacokinetics and metabolism in cirrhotic and noncirrhotic critically ill patients.

http://www.wikidata.org/entity/Q44609131

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年学术文章

@wuu

2003年学术文章

@zh

2003年学术文章

@zh-cn

2003年学术文章

@zh-hans

2003年学术文章

@zh-my

2003年学术文章

@zh-sg

2003年學術文章

@yue

2003年學術文章

@zh-hant

name

Citrate pharmacokinetics and m ...... hotic critically ill patients.

@en

Citrate pharmacokinetics and m ...... hotic critically ill patients.

@nl

type

label

Citrate pharmacokinetics and m ...... hotic critically ill patients.

@en

Citrate pharmacokinetics and m ...... hotic critically ill patients.

@nl

prefLabel

Citrate pharmacokinetics and m ...... hotic critically ill patients.

@en

Citrate pharmacokinetics and m ...... hotic critically ill patients.

@nl

P1433

Q44609131-3EBB125C-81E7-4026-91EB-E1EDE7C00F9F

P1476

Q44609131-E14B36AF-2EE8-4FDC-9757-F3D28292EFC5

P2093

Q44609131-33EA0405-460F-4876-9227-978B306F22FD

Q44609131-389619F4-3535-4D3F-8EA0-4DB14440D8DC

Q44609131-3FFC8283-85C2-4931-90FA-CFE10F5A710D

Q44609131-8B29663D-DBC5-45A8-B038-5E21A73644D3

Q44609131-8D469B6F-B3DA-4D11-8214-612F1EFCAC41

Q44609131-C422AD23-7F38-4BEB-8DA9-04706A6E4A1E

Q44609131-CDE61180-5971-4212-9CA3-4CA0A207B008

P304

Q44609131-AD645E95-711C-4093-99C0-665FD788984E

P31

Q44609131-E9E1B88E-3517-4D1E-8D39-3D939BBE5FDD

P356

Q44609131-DEE4A3B9-FB46-4F99-8E5D-9EE3D52D7F2C

P407

Q44609131-A4EE8E66-3A6D-4596-8AA7-2F93C4D80805

P433

Q44609131-B8D84D00-20EF-4C5D-A2E9-1C73510A7149

P478

Q44609131-D84C04DD-9B77-4877-8D4D-16963FD7D7E8

P577

Q44609131-1E89CCEB-475F-4E95-91A0-95E7E27C4A33

P698

Q44609131-3857FB77-6461-4E9D-8477-206D181AC302

P921

Q44609131-2B29D7A9-55F7-43E3-BAB8-D3DF8B0DDF37

P356

01.CCM.0000084871.76568.E6

P1433

Critical Care Medicine

P1476

Citrate pharmacokinetics and m ...... hotic critically ill patients.

@en

P2093

Alexandra Gendo

http://www.w3.org/2001/XMLSchema#string

Alfred Gangl

http://www.w3.org/2001/XMLSchema#string

Christian Joukhadar

http://www.w3.org/2001/XMLSchema#string

Christian Madl

http://www.w3.org/2001/XMLSchema#string

Edith Bauer

http://www.w3.org/2001/XMLSchema#string

Ludwig Kramer

http://www.w3.org/2001/XMLSchema#string

Wolfram Strobl

http://www.w3.org/2001/XMLSchema#string

P304

2450-2455

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/01.CCM.0000084871.76568.E6

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

31

http://www.w3.org/2001/XMLSchema#string

P577

2003-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

14530750

http://www.w3.org/2001/XMLSchema#string

P921